In NS patients, the urinary loss of antithrombin III contributes to hypercoagulability and a diminished response to heparin, necessitating higher doses to achieve therapeutic anticoagulation, which in turn increases the risk of bleeding or other side effects (Hrish et al., 2001; Cuker, 2016). The gene discussed is SERPINC1; the disease is thrombophilia.